[1] Tozzoli R, Basso SM, D' Aurizio F,et al. Evaluation of predictive value of pleural CEA in patients with pleural effusions and histological findings: A prospective study and literature review[J].Clin Biochem,2016, 49(16-17):1227-1231. [2] 庄正陵,丁俊辉,刘江涛,等. 聚合酶I和转录物释放因子在非小细胞肺癌中表达水平和对迁移侵袭的影响[J].中华实验外科杂志,2018,35(11):2106-2108. [3] Hu CY, Zhang YH, Wang T, et al. Interleukin-2 reverses CD8 (+) T cell exhaustion in clinical malignant pleural effusion of Lung cancer [J].Clin Exp Immunol,2016, 186(1): 106-114. [4] 赖馨,李小峰,陈丽芳,等. IL-22,IL-27,VEGF,TF及TFPI鉴别良恶性胸腔积液的应用价值研究[J].国际检验医学杂志,2016,37(22):3111-3112. [5] Liu L, Qiao Y, Hu C, et al. Endostatin exerts radiosensitizing Effect in non-small cell lung cancer cells by inhibiting VEGFR2 Expression [J].Clin Transl Oncol,2016, 18(1): 18-26. [6] 杜明伟,方长青,王秀茹等. 血管内皮标记物及血管内皮生长因子在胸水细胞中的表达和意义[J].微生物学杂志,2012, 32(4):47-52. [7] 方长清,姜跃峰,姜海娇,等. 恶性胸腔积液中肺腺癌的 EGFR、VEGF 和 P53 的表达及分子生物学意义[J].中国组织化学与细胞化学杂志. 2014,23(3):249-251. [8] Tamiya M, Tamiya A, Yasue T, et al. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker For Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion [J].Anticancer Res,2016, 36(6): 2939-2944.
2019, Vol. 36 
